US FDA Aims For 'Appropriate Balance' For Resuming Inspections Suspended By Pandemic

Phased approach will prioritize the safety of FDA and industry employees while striking ‘an appropriate balance between a scaled-back surveillance inspection program and the continuation of providing robust regulatory oversight,’ Commissioner Hahn says in a memo from self-isolation.